Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 2/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BPTGS2LMNACDC25A | |
| SCHEMBL11603765 | 0.90 | PTGS2 (0.66) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL4413192 | 0.89 | PTGS2 (0.72) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL4266887 | 0.88 | PTGS2 (0.75) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL4404145 | 0.88 | PTGS2 (0.75) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL4410750 | 0.88 | PTGS2 (0.75) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL4273970 | 0.88 | PTGS2 (0.75) | MTNR1AMTNR1BPTGS2LMNAPOLB | |
| SCHEMBL8470343 | 0.84 | HPGD (0.46) | MTNR1AMTNR1BPTGS2LMNACDC25A | |
| SCHEMBL14273054 | 0.84 | PTGS2 (0.79) | PTGS2 | |
| SCHEMBL7419329 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BPTGS2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| CN-113754685-B | Dihydrothiochromene pyrazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-4190789-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| CN-115835863-A | Oxaazabicyclic derivatives, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2022022630-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | MTNR1A 4046/4885MTNR1B 3314/4885PTGS2 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.